Rippl

Invests in preseed, seed (through City Spark Investments), and Series A (through City Light Investments) companies where there is a direct relationship between financial outcomes and measurable social impact.

We back ambitious founders who actively seek to change the status quo.

Early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease

GP at GV, investing across healthcare delivery and neuropsychiatric therapeutics. As a psychiatrist by background, Ben also leads GV’s investments in mental health-related companies, including Headway and Brightline. His investments include Aspire (acquired by Anthem), Rodin (acquired by Alkermes), Carebridge, Patina, Waltz Health, Nym, and Cerevance.

Healthcare and industry-centric investor at General Catalyst.

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150 companies, including 39 which have reached valuations exceeding $1 billion. Mr. Nelsen is focused on generating new ideas for disruptive technologies or business models and partnering with founding management teams and entrepreneurs to execute on these visions by advancing novel platform technologies with the overarching goal of improving health care and outcomes. Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), Juno Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Altos Labs, EQRx, Lyell Immunopharma (LYEL), Array BioPharma (acquired by Pfizer), Unity Biotechnology (UBX), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Rubius Therapeutics (RUBY), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex), and IDUN Pharmaceuticals (acquired by Pfizer). Mr. Nelsen is a director of VIR, SANA, LYEL, National Resilience, Insitro, Prime Medicine, Nutcracker Therapeutics, Maze Therapeutics, Neumora Therapeutics, Brii Biosciences, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.